Telix Pharmaceuticals Limited
9.15USD
-0.3900 (-4.09%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TLX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | A$0.09▲ | A$0.01 | 1 | 0 |
| Next quarter | A$0.09▲ | A$0 | 1 | 0 |
| Current year | A$0.16▲ | A$0.12 | 3 | 1 |
| Next year | -A$0.04▼ | A$0.29 | 0 | 1 |
27 ratings from 5 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wedbush | Reiterated | Outperform | $22 | Oct 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Sep 25, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Sep 23, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Sep 15, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Sep 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Sep 2, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Aug 20, 2026 |
| Citigroup | Maintained | Buy | $22.5 $22 | Jul 7, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Jul 7, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Jul 6, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Apr 13, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Apr 13, 2026 |
| Wedbush | Reiterated | Outperform | $22 | Apr 7, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Apr 7, 2026 |
| Citigroup | Maintained | Buy | $22 $22.5 | Feb 24, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Jan 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Dec 22, 2025 |
| UBS | Maintained | Buy | $23 $20 | Sep 23, 2025 |
| Citigroup | Initiated | Buy | $22 | Sep 18, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23 $20 | Sep 10, 2025 |
| JP Morgan | Downgraded from Overweight | Neutral | — | Aug 28, 2025 |
| Wedbush | Reiterated | Outperform | $22 | Aug 28, 2025 |
| HC Wainwright & Co. | Initiated | Buy | $23 | Jul 3, 2025 |
| Wedbush | Reiterated | Outperform | $22 | Jun 12, 2025 |
| Wedbush | Initiated | Outperform | $22 | Jun 5, 2025 |
1 filing from 1 insider · 0 buy / 0 sell over 6m
Officers and directors of TLX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smith Darren CharltonOfficer, Group Chief Financial Officer | Buy | 2.1k | $9.66 | $20k | Sep 7, 2026 |
No analyst notes on TLX yet.
Analyst Ratings
4 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 5 | 0 | 0 | 0 | Buy2.00 |
| 1 mo ago | 0 | 5 | 0 | 0 | 0 | Buy2.00 |
| 2 mo ago | 0 | 5 | 0 | 0 | 0 | Buy2.00 |
| 3 mo ago | 0 | 5 | 0 | 0 | 0 | Buy2.00 |
Members whose judged calls on TLX have played out most reliably.
No settled calls on TLX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice